Prime Medicine (PRME) Competitors $2.00 +0.05 (+2.56%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$1.98 -0.02 (-1.25%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock PRME vs. BGM, MLYS, NRIX, VIR, NTLA, COLL, RCUS, RCKT, XNCR, and ZYMEShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include Qilian International Holding Group (BGM), Mineralys Therapeutics (MLYS), Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Intellia Therapeutics (NTLA), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Rocket Pharmaceuticals (RCKT), Xencor (XNCR), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Prime Medicine vs. Qilian International Holding Group Mineralys Therapeutics Nurix Therapeutics Vir Biotechnology Intellia Therapeutics Collegium Pharmaceutical Arcus Biosciences Rocket Pharmaceuticals Xencor Zymeworks Qilian International Holding Group (NASDAQ:BGM) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Does the media refer more to BGM or PRME? In the previous week, Prime Medicine had 9 more articles in the media than Qilian International Holding Group. MarketBeat recorded 10 mentions for Prime Medicine and 1 mentions for Qilian International Holding Group. Qilian International Holding Group's average media sentiment score of 1.87 beat Prime Medicine's score of 0.70 indicating that Qilian International Holding Group is being referred to more favorably in the media. Company Overall Sentiment Qilian International Holding Group Very Positive Prime Medicine Positive Do institutionals and insiders believe in BGM or PRME? 70.4% of Prime Medicine shares are held by institutional investors. 58.7% of Qilian International Holding Group shares are held by company insiders. Comparatively, 23.5% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, BGM or PRME? Qilian International Holding Group has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Is BGM or PRME more profitable? Qilian International Holding Group's return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Qilian International Holding GroupN/A N/A N/A Prime Medicine N/A -107.87%-74.97% Does the MarketBeat Community prefer BGM or PRME? Prime Medicine received 28 more outperform votes than Qilian International Holding Group when rated by MarketBeat users. CompanyUnderperformOutperformQilian International Holding GroupN/AN/APrime MedicineOutperform Votes2866.67% Underperform Votes1433.33% Do analysts recommend BGM or PRME? Prime Medicine has a consensus target price of $13.38, suggesting a potential upside of 568.75%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts clearly believe Prime Medicine is more favorable than Qilian International Holding Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Qilian International Holding Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prime Medicine 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Which has better valuation & earnings, BGM or PRME? Qilian International Holding Group has higher revenue and earnings than Prime Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQilian International Holding Group$25.10M44.20-$1.44MN/AN/APrime Medicine$2.98M87.94-$198.13M-$1.65-1.21 SummaryPrime Medicine beats Qilian International Holding Group on 9 of the 15 factors compared between the two stocks. Remove Ads Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$262.32M$3.04B$5.64B$19.62BDividend YieldN/A1.54%4.57%3.75%P/E Ratio-0.9829.2923.1333.60Price / Sales87.94436.17383.8927.47Price / CashN/A168.6838.1617.54Price / Book1.463.956.944.60Net Income-$198.13M-$71.95M$3.20B$1.02B7 Day Performance2.56%-3.76%-2.32%0.37%1 Month Performance-20.63%-10.33%2.84%-2.45%1 Year Performance-71.43%-27.15%10.75%5.03% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine2.8754 of 5 stars$2.00+2.6%$13.38+568.8%-70.4%$262.32M$2.98M-0.98234BGMQilian International Holding GroupN/A$10.94-0.5%N/AN/A$1.06B$25.10M0.00298Positive NewsGap UpMLYSMineralys Therapeutics3.2887 of 5 stars$16.17-4.1%$27.00+67.0%+17.4%$1.02BN/A-4.4428High Trading VolumeNRIXNurix Therapeutics2.0442 of 5 stars$13.34+2.7%$30.88+131.5%-13.7%$1.01B$54.55M-4.62300VIRVir Biotechnology3.6132 of 5 stars$7.20+3.9%$35.67+395.4%-34.0%$987.43M$63.71M-1.84580NTLAIntellia Therapeutics4.4821 of 5 stars$9.31+3.4%$37.56+303.4%-68.9%$963.74M$57.88M-1.71600Analyst RevisionGap UpCOLLCollegium Pharmaceutical4.0812 of 5 stars$30.56+1.7%$43.60+42.7%-27.7%$962.21M$631.45M13.17210Analyst RevisionRCUSArcus Biosciences2.332 of 5 stars$9.15+2.3%$30.25+230.8%-53.5%$961.49M$258M-2.90500Gap DownRCKTRocket Pharmaceuticals4.671 of 5 stars$8.73+3.6%$43.00+392.6%-71.1%$930.88MN/A-3.17240Positive NewsXNCRXencor3.4825 of 5 stars$12.95-1.9%$34.38+165.4%-48.7%$912.48M$110.49M-4.05280ZYMEZymeworks2.6648 of 5 stars$13.05+2.6%$21.00+60.9%+21.5%$907.98M$76.30M-8.70460Insider TradePositive News Remove Ads Related Companies and Tools Related Companies Qilian International Holding Group Alternatives Mineralys Therapeutics Alternatives Nurix Therapeutics Alternatives Vir Biotechnology Alternatives Intellia Therapeutics Alternatives Collegium Pharmaceutical Alternatives Arcus Biosciences Alternatives Rocket Pharmaceuticals Alternatives Xencor Alternatives Zymeworks Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRME) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRME Stock Free PRME Stock Alerts